Search Results

Artificial intelligence won’t replace people in biopharma, but it is infiltrating every step of drug development, including in some ways that aren’t so obvious.

VGXI, Inc. has entered into a strategic partnership with Sutro Biopharma, Inc. to support clinical production of luveltamab tazevibulin, abbreviated as “luvelta”, a novel Folate Receptor-α -targeting antibody-drug conjugate with the potential to address the unmet need in several FRα-expressing cancers.

Akeso, Inc. (9926.HK) (“Akeso,” “we,” or the “Company”) today announced that Michelle Xia , Ph.D, the founder, chairwoman, president, and CEO of Akeso, will deliver a keynote speech focusing on the Company’s achievements in the development of new bispecific antibody drug therapeutics and the Company’s 2024 key milestones at the 42nd Annual J.P. Morgan Healthcare Conference, to be held January 8-11, 2024 in San Francisco, California.

Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) today announced financial and operational results for the first quarter of 2024.

Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.